Clusterin expression predicts survival of invasive cervical cancer patients treated with radical hysterectomy and systematic lymphadenectomy

Gynecologic Oncology

Volumn 108, Issue 3, 2008, Pages 527-532

  Watari, Hidemichi ^a   Ohta, Yoko ^a   Hassan, Mohamed Kamel ^a   Xiong, Ying ^a   Tanaka, Shinya ^a   Sakuragi, Noriaki ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cervical cancer; Clusterin; Immunohistochemistry; Lymphnode metastasis; Prognostic factor

Indexed keywords

CLUSTERIN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADICAL HYSTERECTOMY; UTERINE CERVIX CANCER;

EID: 39249084676     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.11.026     Document Type: Article

References (34)

1. Sakuragi N., Satoh C., Takeda N., Hareyama H., Takeda M., Yamamoto R., et al. Incidence and distribution pattern of pelvic and paraaortic lymph node metastasis in patients with stages Ib, IIa, and IIb cervical carcinoma treated with radical hysterectomy. Cancer 85 (1999) 1547-1554
2. Sakuragi N., Takeda N., Hareyama H., Fujimoto T., Todo Y., Okamoto K., et al. A multivariate analysis of blood vessel and lymph vessel invasion as predictors of ovarian and lymph node metastases in patients with cervical carcinoma. Cancer 88 (2000) 2578-2583
3. Takeda N., Sakuragi N., Takeda M., Okamoto K., Kuwabara M., Negishi H., et al. Multivariate analysis of histopathologic prognostic factors for invasive cervical cancer treated with radical hysterectomy and systematic retroperitoneal lymphadenectomy. Acta Obstet Gynecol Scand 81 (2002) 1144-1151
4. Rosenberg M.E., and Silkensen J. Clusterin: physiologic and pathophysiologic considerations. Int Biochem Cell Biol 27 (1995) 633-645
5. Steinberg J., Oyasu R., Lang S., Sintich S., Rademaker A., and Lee C. Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer. Clin Cancer Res 3 (1997) 1707-1711
6. Miyake H., Hara I., Kamidono S., and Gleave M.E. Synergistic chemosensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Clin Cancer Res 7 (2001) 4245-4252
7. Redondo M., Villar E., Torres-Munoz J., Tellez T., Morell M., and Pelito C.K. Overexpression of clusterin in human breast carcinoma. Am J Pathol 157 (2002) 393-399
8. Pucci S., Bonanno E., Pichiorri F., Angeloni C., and Spagnoli L.G. Modulation of different clusterin isoforms in human colon tumorigenesis. Oncogene 23 (2004) 2298-2304
9. Kurahashi T., Murakami M., Yamanaka K., Hara I., and Miyake H. Expression of the secreted form of clusterin protein in renal cell carcinoma as a predictor of disease extension. BJU Int 96 (2005) 895-899
10. Zellweger T., Miyake H., July L.V., Akbari M., Kiyama S., and Gleave M.E. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Neoplasia 3 (2001) 360-367
11. Chung J., Kwak C., Jin R.J., Lee C.H., Lee K.H., and Lee S.E. Enhanced chemosensitivity of bladder cancer cells to cisplatin by suppression of clusterin in vitro. Cancer Lett 203 (2004) 155-161
12. July L.V., Beraldi E., So A., Fazil L., Evans K., English J.C., et al. Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. Mol Cancer Ther 3 (2004) 223-232
13. Trougakos I.P., So A., Jansen B., Gleave M.E., and Gonos E.S. Silencing expression of the clusterin/apolipoprotein J gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress. Cancer Res 64 (2004) 1834-1842
14. So A., Sinnemann S., Huntsman D., Fazil L., and Gleave M.E. Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo. Mol Cancer Ther 4 (2005) 1837-1849
15. Zellweger T., Chi K., Miyake H., Adomat H., Kiyama S., Skov K., et al. Enhanced radiosensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin Cancer Res 8 (2002) 3276-3284
16. Cao C., Shinohara E.T., Li H., Niermann K.J., Kim K.W., Sekhar K.R., et al. Clusterin as a therapeutic target for radiation sensitization in a lung cancer model. Int J Radiat Oncol Biol Phys 63 (2005) 1228-1236
17. Yamanaka K., Gleave M., Muramaki M., Hara I., and Miyake H. Enhanced radiosensitivity by inhibition of the anti-apoptotic gene clusterin using antisense oligodeoxynucleotide in a human bladder cancer model. Oncol Rep 13 (2005) 885-890
18. Miyake H., Gleave M.E., Kamidono S., and Hara I. Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence. Urology 59 (2002) 150-154
19. Miyake H., Hara S., Arakawa S., Kamidono S., and Hara I. Overexpression of clusterin is an independent prognostic factor for nonpapillary renal cell carcinoma. J Urol 167 (2002) 703-706
20. Miyake H., Yamanaka K., Muramaki M., Kurahashi T., Gleave M.E., and Hara I. Enhanced expression of the secreted form of clusterin following neoadjuvant hormonal therapy as a prognostic predictor in patients undergoing radical prostatectomy for prostate cancer. Oncol Rep 14 (2005) 4581-4588
21. Kruger S., Ola V., Fisher D., Feller A.C., and Friedrich M. Prognostic significance of clusterin immunoreactivity in breast cancer. Neoplasma 54 (2007) 46-50
22. Miyake H., Muramaki M., Kurahashi T., Yamanaka K., Hara I., Gleave M.E., et al. Expression of clusterin in prostate cancer correlates with Gleason score but not with prognosis in patients undergoing radical prostatectomy without neoadjuvant hormonal therapy. Urology 68 (2006) 609-614
23. Park D.C., Yeo S.G., Shin E.Y., Mok S.C., and Kim D.H. Clusterin confers paclitaxel resistance in cervical cancer. Gynecol Oncol 103 (2006) 996-1000
24. Hassan M.K., Watari H., Christenson L.K., Bettuzzi S., and Sakuragi N. Involvement of changes and intracellular trafficking of different clusterin isoforms in the chemo-resistance of ovarian cancer cells. Proceeding of 99th annual meeting of AACR (2007) abstract#2341
25. Tinga D.J., Timmer P.R., Bouma J., and Aalders J. Prognostic significance of single versus multiple lymph node metastases in cervical carcinoma stage IB. Gynecol Oncol 39 (1990) 175-180
26. Inoue T., and Morita K. The prognostic significance of number of positive nodes in cervical carcinoma stage IB, IIA, and IIB. Cancer 65 (1990) 1923-1927
27. Wertheim M.S., Hakes T.B., Daghestani A.N., Nori D., Smith D.H., and Lewis J.L. A pilot study of adjuvant therapy in patients with cervical cancer at high risk of recurrence after radical hysterectomy and pelvic lymphadenectomy. J Clin Oncol 3 (1985) 912-916
28. Killackey M.A., Boardman L., and Carroll D.S. Adjuvant chemotherapy and radiation in patients with poor prognostic stage IB/IIA cervical cancer. Gynecol Oncol 49 (1993) 377-379
29. Lai C., Lin T., Soong Y., Phil M., and Chen H. Adjuvant chemotherapy after radical hysterectomy for cervical carcinoma. Gynecol Oncol 35 (1989) 193-198
30. Tattersall M.H.N., Ramirez C., and Coppleson M. A randomized trial of adjuvant chemotherapy after radical hysterectomy in stage IB-IIA cervical cancer patients with pelvic lymph node metastases. Gynecol Oncol 46 (1992) 176-181
31. Miyake H., Hara S., Zellweger T., Kamidono S., Gleave M.E., and Hara I. Acquisition of resistance to Fas-mediated apoptosis by overexpression of clusterin in human renal cell carcinoma cells. Mol Urol 5 (2001) 105-111
32. Miyake H., Tolcher A., and Gleave M.E. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. J Natl Cancer Inst 92 (2000) 34-41
33. Chi K.N., Gleave M.E., Klasa R., Murray N., Bryce C., Lopes de Menezes D.E., et al. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res 7 (2001) 3920-3927
34. Chi K.N., Eisenhauer E., Fazil L., Jones E.C., Goldenberg S.L., Powers J., et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 97 (2005) 1287-1296